RCM
PACB icon

Rotella Capital Management’s Pacific Biosciences PACB Stock Holding History

Rotella Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-19,866
Closed -$123K – 376
2014
Q2 		$123K Buy
+19,866
New +$99.4K 0.1% 189

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rotella Capital Management's PACB Position: Q3 2014 in Review

Rotella Capital Management sold out of Pacific Biosciences (PACB) in Q3 2014, closing a stake of 19,866 shares — an estimated $123K sold.

Rotella Capital Management first reported a position in PACB in Q2 2014 and held it in 1 quarter. The position peaked at $123K in Q2 2014. 88 funds tracked by Wall St. Rank hold PACB as of Q3 2014.

  • Rotella Capital Management reported no remaining Pacific Biosciences position as of Q3 2014 after selling out during the quarter.
  • Rotella Capital Management sold 19,866 Pacific Biosciences shares in Q3 2014, an estimated $123K.
  • Rotella Capital Management first reported a position in Pacific Biosciences in Q2 2014 and held it in 1 quarter.
  • Rotella Capital Management's Pacific Biosciences position peaked at $123K in Q2 2014.
  • 88 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2014.

Based on Rotella Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.